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Crizotinib is the first anaplastic lymphoma kinase (ALK) inhibitor to have been approved for the treatment of non–small
cell lung cancer (NSCLC) harboring an ALK fusion gene, but it has been found that, in the clinic, patients develop
resistance to it. Alectinib and ceritinib are second-generationALK inhibitorswhich show remarkable clinical responses in
both crizotinib-naive and crizotinib-resistant NSCLC patients harboring an ALK fusion gene. Despite their impressive
activity, clinical resistance to alectinib and ceritinib has also emerged. In the current study, we elucidated the resistance
mechanisms to these second-generation ALK inhibitors in the H3122 NSCLC cell line harboring the EML4-ALK variant 1
fusion in vitro. Prolonged treatment of the parental H3122 cells with alectinib and ceritinib led to two cell lines which are
10 times less sensitive to alectinib and ceritinib than the parental H3122 cell line. Althoughmutations of ALK in its kinase
domain are a common resistance mechanism for crizotinib, we did not detect any ALK mutation in these resistant cell
lines. Rather, overexpression of phospho-ALK and alternative receptor tyrosine kinases such as phospho-EGFR,
phospho-HER3, andphospho-IGFR-1Rwasobserved in both resistant cell lines.Additionally, NRG1, a ligand forHER3, is
upregulated and responsible for resistance by activating the EGFR family pathways through theNRG1-HER3-EGFR axis.
Combination treatment with EGFR inhibitors, in particular afatinib, was shown to be effective at overcoming resistance.
Our study provides newmechanistic insights into adaptive resistance to second-generationALK inhibitors and suggests
a potential clinical strategy to combat resistance to these second-generation ALK inhibitors in NSCLC.
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The unprecedented success enjoyed by epidermal growth factor
receptor (EGFR) inhibitors in the treatment of non–small cell lung
cancer (NSCLC) patients with an EGFR active mutation has made
targeted therapy a promising new anticancer strategy for NSCLC [1].
Specific genetic alterations of anaplastic lymphoma kinase (ALK) [2];
hepatocyte growth factor receptor, also known as MET [3]; Kirsten
rat sarcoma viral oncogene homolog (KRAS) [4]; B-Raf proto-
oncogene [5]; Ros proto-oncogene1 (Ros1) [6]; and Ret proto-
oncogene [7] were subsequently identified, and small-molecule
inhibitors that target these specific tyrosine kinases have beenpursued as novel anticancer treatments for NSCLC [8]. Crizotinib, a
potent ALK inhibitor, has demonstrated impressive clinical activity in
NSCLC patients whose tumors harbor the EML4-ALK fusion gene
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treatment of NSCLC [2]. Unfortunately, most patients treated with
crizotinib relapse after a remarkable initial response, with a median
progression-free survival of 10.5 months in clinical trials [9]. Various
mutations in the ALK kinase domain, alternative bypass pathway
activation, and epithelial to mesenchymal transition have been
identified as contributors to crizotinib resistance [9–12].
To overcome crizotinib resistance, second-generation ALK
inhibitors have been developed. Ceritinib (LDK378) was the first
second-generation ALK inhibitor approved by the US Food and Drug
Administration (FDA) in 2014 and is now being used for the
treatment of NSCLC patients who had progressed during crizotinib
treatment or were intolerant of crizotinib [13,14]. Another
second-generation ALK inhibitor, alectinib (CH5424802), has also
shown impressive responses in clinical studies in crizotinib-naive or
crizotinib-resistant ALK-positive NSCLC patients [15–17]. These
two second-generation ALK inhibitors are not only more efficacious
than crizotinib but also show activity toward the resistant ALK
mutations that arise during crizotinib treatment.
Perhaps unsurprisingly, a number of recent studies have now
shown that resistance also develops to alectinib and ceritinib in both
preclinical settings and in ALK-positive patients. Novel ALK-
resistant mutations (V1180L and G1123S) and refractory ALK-
resistant mutations (G1202R and F1174C) have been reported to
exhibit resistance to these second-generation ALK inhibitors [18–
21]. The V1180L-resistant mutation to alectinib was developed in
an in vitro study using an NSCLC cell line but is still sensitive to
ceritinib. The ALK-G1123S mutation was identified in an NSCLC
patient who progressed on ceritinib treatment, but this patient was
still responsive to alectinib treatment, suggesting that the G1123S
ALK mutation is sensitive to alectinib. However, the ALK-G1202R
and F1174C mutations showed significant resistance to both alectinib
and ceritinib. Moreover, in an ongoing clinical study with ceritinib,
several patients (6 out of 10, 60%) developed ceritinib resistance, but
their tumors did not harbor any detectable ALK-resistant mutations
[13]. These clinical data suggest that, in addition to ALK mutations,
other resistance mechanisms exist for these second-generation
ALK inhibitors.
In this study, we have investigated the mechanisms of resistance to
ceritinib and alectinib using the NCI-H3122 NSCLC cell line which
harbors the EML4-ALK fusion gene variant 1.Our data showed that no
ALK-resistant mutations were detected when the NCI-H3122 cells
acquired resistance in vitro to these next-generation ALK inhibitors.
Instead, the primary resistance mechanism to ceritinib and alectinib
found in our study was the activation of alternative receptor tyrosine
kinase (RTK) pathways, in particular the NRG1-HER3-EGFR axis.
Accordingly, we explored strategies to overcome resistance to these
second-generation ALK inhibitors and found that the combination of
ALK inhibitors with afatinib, a small-molecule inhibitor targeting both
wild-type and mutated EGFR, is effective in overcoming resistance to
these second-generation ALK inhibitors.
Materials and Methods
Reagents
Alectinib (CH5424802), ceritinib (LDK378), crizotinib, erlotinib,
AZD9291, AZD 8931, afatinib, AP26113, and PF06463922 were
purchased from Selleckchem (Houston, TX). Epithelial growth factor
(EGF), amphiregulin, neuregulin-1 (NRG1), and insulin growthfactor (IGF) were purchased from R&D systems (Minneapolis, MN).
All reagents were stored at −20°C.
Cell Culture and Cell Viability Assay
The NCI-H3122 cell line harboring the fusion gene
EML4-ALK variant 1, and the Karpas 299 cell line and the
SU-DHL-1 cell line harboring the fusion gene NPM-ALK were
purchased from American Type Culture Collection (Manassas,
VA) and cultured in RPMI1640 medium (Gibco, Grand Island,
NY) containing 10% fetal bovine serum (Gibco). Cells were
maintained in a cell culture incubator at 37°C in a humidified
atmosphere with 5% CO2.
Cell viability was evaluated by a WST-8 [2-(2-methoxy-4-
nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazo-
lium, monosodium salt] assay (Dojindo Molecular Technologies,
Inc., Rockville, MD). Cells were plated in 96-well plates and cultured
overnight to allow cells to attach, and then the drug was added at
indicated concentrations for 96 hours. Cell culture media containing
the drug were washed, 10% WST-8 dye (100 μl) was added to each
well and incubated for an additional hour, and the absorbance at 450
nm was measured in a microplate reader (Molecular Devices,
Sunnyvale, CA). Cell growth inhibition was evaluated as the ratio
of the absorbance of the drug-treated samples to that of the
DMSO-treated control and analyzed by Prism 6 software. All
experiments were carried out in triplicate.
Establishment of In Vitro ALK Resistance Models
Alectinib- and ceritinib-resistant models were established by
exposing cells to a high drug concentration (1 μM) for 3 days. The
drug-tolerant cells were allowed to expand and regain proliferation
rates comparable to those of the parental cells. The surviving cells
were then exposed to drugs again for 3 days. This process was repeated
until the cells grew at a comparable rate in either the absence or the
presence of 1 μM alectinib or ceritinib.
Reverse Transcriptase Polymerase Chain Reaction (RT-PCR),
Sequencing, Quantitative Real-Time PCR (qRT-PCR)
Total RNA was isolated from 5 × 105 cells using the RNeasy Mini
Kit (Qiagen, Valencia, CA), cDNA was generated via a SuperScript
III one-step RT-PCR system (Invitrogen, Carlsbad, CA) according to
manufacturer’s instructions, and cDNA was then PCR amplified with
specific primers that cover the whole ALK kinase domain coding
region (primers: forward: GTACAAGCTGAGCAAGCTCCGCAC;
reverse: AGGCACTTTCTCTTCCTCTTCCAC) [9]. The PCR
products were purified using a PCR Purification Kit (Qiagen) prior to
Sanger dideoxynucleotide sequencing (Sequencing Core at the University
of Michigan). For qRT-PCR, Taqman probes ALK (Hs01058318_m1),
EGFR (Hs01076078_m1), HER3 (Hs00176538_m1), IGF-1R
(Hs00609566_m1 ) , EGF (H s01099999_m1 ) , IGF
(Hs01547656_m1), amphiregulin (Hs00950669_m1), NRG1
(Hs00247620_m1), and GAPDH (Hs02758991_g1) as an endogenous
control were purchased from Life Technologies (Carlsbad, CA).
qRT-PCR was performed according to manufacturer’s instructions,
and data were analyzed using the△△Ct method.
Western Blotting and Phospho-RTK Array
Total protein was isolated from cells as indicated in each experiment.
The following primary antibodies were used and purchased from Cell
Signaling Technology (Beverly, MA): rabbit anti-total EGFR, total
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phospho-ALK (pTry1604), phospho-EGFR (pTyr1068), phospho-
HER3 (pTyr1222), phospho-IGF-1R (pTry1135), phospho-ERK1/2
(pThr202/Tyr204), and phospho-AKT (pSer473). The primary
antibodies were diluted 1:1000 in blocking buffer and incubated with
the membranes overnight at 4°C. Membranes were washed with
Tris-Buffered Saline and Tween 20 (TBST) buffer three times, and goat
anti-rabbit IgG secondary antibody was applied for 1 hour at room
temperature.HRP-conjugated anti-GAPDHantibodywas purchased from
Life Technologies and diluted 1:2000 for use.
To detect phosphorylation of human kinases, the Proteome
Profiler Human Phospho-Kinase Array Kit from R&D Systems
(Minneapolis, MN) was employed. For this assay, 300 μg of total
proteins was isolated from cells, and the Phospho-Kinase Array Kit
was used according to manufacturer’s instructions to detect the
phosphorylation of 43 human kinases.
Immunoprecipitation Assay
A total of 1000 μg of protein was extracted from cells; then 1 μg of
anti-HER3 antibody (Cell Signaling Technology) was added to the
protein lysate and incubated for 1 hour at 4°C with gentle mixing. For
each sample, 20 μl of Protein A Agarose beads (Sigma-Aldrich, St.
Louis, MO) was added to 1.5-ml tubes and washed with lysis buffer
four times before being added to the protein lysate containing the
anti-HER3 antibody and incubated overnight at 4°C. The beads
containing the antibody-target protein complexes were washed five
times and then pelleted by centrifugation, SDS loading buffer was
added, and samples were boiled for 5 minutes to separate beads and
proteins. Beads were pelleted by centrifugation, and supernatants
were collected and submitted to Western blot analysis for detection of
p-EGFR as described above. EGFR pulled-down products were also
collected to detect p-HER3 presence, and EGFR antibody forFigure 1. Development of two ALK models resistant to alectini
second-generation ALK inhibitors. (A and B) Second-generation ALK
alectinib) and LDKR H3122 (developed by exposing to ceritinib) wer
determined by WST assay. Resistant cells showed 10-fold lower d
inhibitors. (C–E) Both resistant cell lines also showed different leve
additional two novel ALK inhibitors, AP26113 and PF06463922. (Dataimmunoprecipitation (IP) study was also purchased from Cell
Signaling Technology.
Transfection of siRNA
siRNAs [ON-TARGET plus Human ERBB3 (2065) siRNA–
SMART pool, L-003127-00] against the HER3 target sequence
purchased from GE Healthcare (Pittsburgh, PA) were used to knock
down HER3. Cells were seeded in six-well plates, and siRNAs were
transfected into cells with the help of Lipofectamine RNAiMAX
(Invitrogen) according to the manufacturer’s protocol.
Software and Statistical Analysis
Dose-response curves were analyzed using Graphpad Prism 6
software. qRT-PCR data were analyzed using the ΔΔCt method,
normalized to the proper housekeeping gene (GAPDH).
Results
Establishment of Two Adaptive Drug Resistance Cell Models to
Alectinib and Ceritinib
Two adaptive drug resistance cell models, to alectinib and ceritinib,
were generated by exposing H3122 cells harboring the EML4-ALK
variant 1 to these drugs for an extended period of time. After 5
months of intermittent exposure to 1 μM alectinib, the cells became
resistant and were named CHR H3122. After 7 months of
intermittent exposure to 1 μM ceritinib (LDK378), the cells became
resistant and were named LDKR H3122. Both resistant cells were
then cultured in the presence of 1 μM of their respective ALK
inhibitor to maintain their resistance. As shown in Figure 1, A and B,
the resistant cells displayed approximately 10-fold lower sensitivities
to ALK inhibitors when compared with the parental cells. Cross--
resistance to these two ALK inhibitors was also observed (Figure 1, A
and B). Additionally, both CHR H3122 and LDKR H3122 cellsb and ceritinib conferring cross-resistance to crizotinib and all
inhibitors resistant cells CHR H3122 (developed by exposing to
e treated with alectinib or ceritinib for 4 days; cell viabilities were
rug sensitivity and were resistant to both second-generation ALK
ls of resistance to the first-generation ALK inhibitor crizotinib and
were representative of three independent experiments)
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AP26113 and PF06463922, two other new-generation ALK inhibitors
currently in clinical development [22,23] (Figure 1, C–E).
We next investigated if the resistance is permanent or reversible.
When the CHR H3122 and LDKR H3122 resistant cell line pools
were cultured in drug-free media, the resistant cells regained their
sensitivities to both ALK inhibitors after 6 weeks. We also attempted
to identify single-cell resistant clones by expanding single cells in
drug-free media and found that all the expanded clones lost
their resistance to ALK inhibitors during this process. These data
clearly show that the resistance developed to alectinib and ceritinib
is reversible.
To further investigate if the resistant cells existed de novo in the
parental cell pools or if the resistance was gained during drug treatment,
the parentalH3122 cells were seeded in 96-well plates (one cell per well)
(see Supplementary Information 1) to generate single-cell clones. After
3 weeks of culture, these single-cell clones were examined for their
proliferative rate and their sensitivity to alectinib in a cell growth assay.
Our data showed that, in the bulk of tumor cells, individual clones
possessed different proliferative rates. Clones with higher proliferative
rates were more sensitive to alectinib, and three relatively quiescent
clones were less sensitive to alectinib. Interestingly, once these quiescent
clones expanded, they displayed sensitivities to alectinib similar to those
of the sensitive clones.
Based upon our data, we propose that the H3122 parental cell line
has considerable heterogeneity, and a small population of cells
(dormant cells) has a lower proliferative rate and exhibits considerable
de novo resistance to ALK inhibitors. Furthermore, when the H3122
parental cell line was treated with new-generation ALK inhibitors,
these small population drug-tolerant cells became dominant in the
presence of an ALK inhibitor but lost their resistance once expanded
in the absence of the drug.
Evaluation of ALK-Resistant Mutations and Phospho-ALK
Levels in Resistant Cells
ALK mutations and overexpression have been identified as
important resistance mechanisms for ALK inhibitors [9,10,18–21].
We next determined if ALK mutations were developed in the resistant
cells obtained from our study.Figure 2. Upregulation of activated p-ALK contributes to drug resist
indicated concentrations of drugs for 1 hour and then collected for
primary antibodies. (C) Total RNA was isolated from cells and q
manufacturer’s instructions. GAPDH primer was used for normalizin
experiments have been repeated three times)We isolated the total RNAs from the CHR H3122 and LDKR
CHR H3122 cell pools. Sanger dideoxynucleotide sequencing using
ALK-specific primers which expand the whole ALK kinase domain
(1006 bp) was performed but failed to identify any mutation in the
ALK kinase domain in both the CHR H3122 and LDKR CHR
H3122 cell pools. Additionally, we performed Sanger sequencing of
dozens of single-cell clones derived from the resistant cell pools and
again failed to detect any ALK mutation (data not shown).
We next determined the levels of ALK mRNA by qRT-PCR, and
total ALK protein and phospho-ALK by Western blot. A two-fold
increase in the levels of ALKmRNA was detected in both resistant cell
lines (Figure 2C), but no changes in the total ALK protein levels were
observed in these resistant cells or in the resistant cells treated with
either alectinib or ceritinib (Figure 2A and B). Interestingly, although
the levels of p-ALK (Tyr1604) were slightly reduced upon treatment
with either alectinib or ceritinib in the parental cells, both resistant
cell lines have upregulation of p-ALK upon treatment with these ALK
inhibitors at all doses tested (Figure 2A and B). These results show
that p-ALK levels had been increased in the resistant cells and these
new generation ALK inhibitors are also unable to reduce the levels of
pALK in the resistant cells.
Alternative Activation of Receptor Tyrosine Kinase Pathways
(RTK) as a Major Mechanism Mediating Adaptive Drug
Resistance to New Generation ALK Inhibitors
Activation of alternative RTK pathways is known to be an
important drug resistance mechanism for different classes of RTK
inhibitors. Previous reports have also identified activation of EGFR,
KIT, and some other RTK pathways as important resistance
mechanisms for crizotinib [9,11,24–26].
To investigate activation of RTK in both CHR H3122 cells and
LDKR H3122 cells without bias, we employed an RTK array and
found that both resistant cell lines displayed a significant increase of
phospho-EGFR protein (Figure 3A). Increased levels of phos-
pho-IGF-1R and phospho-HER3 were also observed in the LDKR
H3122 cells (Figure 3A).
We investigated mRNA levels of these RTKs by qRT-PCR and
found that levels of EGFR mRNA, HER3 mRNA, and IGF-1R
mRNA were all increased in the resistant cells (Figure 3B). Inance. (A and B) Parental and resistant cells were treated with the
protein isolation. Western blot was performed using the indicated
RT-PCR was performed with ALK-specific primers according to
g ALK mRNA expression levels (P b .001***, P b .0001****). (All
Figure 3. RTKs alternative pathway activation contributes to resistance to second-generation ALK inhibitors. (A) Three hundred
micrograms of proteins was isolated from cells and then used in the RTK array according to manufacturer’s instructions; compared with
parental H3122 cells, CHR H3122 cells showed upregulation of phosphor-EGFR, and LDKR H3122 cells showed upregulation of
phosphor-EGFR, phosphor-IGF-1R, and phosphor-HER3. (B) Total RNA was isolated from H3122, CHR H3122, and LDKR H3122 cells and
analyzed by qRT-PCR, demonstrating overexpression of RTKs in the resistant cells (P b .001***, P b .0001****). (C and D) Cells were
treated with indicated drugs for 1 hour; immunoblotting for RTKs in both resistant cell lines showed upregulation of phosphor-EGFR and
phosphor-HER3 when compared with parental cells. (All experiments have been repeated three times)
166 Resistance Mechanisms to ALK Inhibitors in NSCLC Dong et al. Neoplasia Vol. 18, No. 3, 2016particular, the mRNAs of HER3 and IGF-1R were increased by more
than five-fold.
Western blotting analysis (Figure 3, C and D) showed that
although no obvious increase in the total level of EGFR protein was
detected in both resistant cell lines, the level of p-EGFR (Tyr1068)Figure 4. Role of RTK ligands in the development of acquired resis
performed using specific primers for EGF, IGF, and NRG1. GAPDH
Parental H3122 cells were seeded in 96-well plates overnight to al
concentrations of ALK inhibitors in the presence of indicated EGFR
ligand (IGF) at a concentration of 100 ng/ml for 4 days. WST was per
incubated with different concentrations of NRG1 and stepwise incre
then performed.was significantly increased. Similarly, whereas the total HER3 and
IGF-1R protein levels were not changed in both resistant cell lines,
the levels of p-HER3 (Tyr 1222) and p-IGF-1R (Try 1135) were
greatly increased. AKT and ERK kinases are downstream signaling
molecules of ALK, EGFR, HER3, and IGF-1R kinases, and whereastance. (A) Total mRNA was isolated from cells and qRT-PCR was
was used as internal reference (P b .001***, P b .0001****). (B)
low for attachment and were incubated with stepwise increased
ligands (EGF and amphiregulin), HER3 ligand (NRG1), and IGF1R
formed to evaluate cell viabilities. (C–F) Parental H3122 cells were
ased concentrations of ALK inhibitors for 4 days. WST assay was
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resistant cell lines as comparedwith the parentalH3122 cell line, the levels
of p-AKT (Ser473) and p-ERK (Thr202/Try204) proteinswere increased
in the resistant cell lines. Notably, whereas both alectinib and ceritinib
effectively reduce the levels of p-AKT (Ser473) and p-ERK (Thr202/
Try204) proteins in a dose-dependent manner in the parental H3122 cell
line, these ALK inhibitors are ineffective in reducing the levels of p-AKT
(Ser473) and p-ERK (Thr202/Try204) proteins in both resistant cell
lines. Interestingly, although the AXL pathwaywas reported to contribute
to crizotinib resistance, we did not observe an increase of p-AXL
expression in both resistant cell lines (data not shown).
Increased Expression of EGF-Like Ligand NRG1 as a Major
Contributor to Resistance
Wenext asked how these RTKs are activated. Previous work revealed
that the ligands of RTKs secreted in a tumor microenvironment were
the main contributors of RTK activation [9,25,27]. Hence, we
investigated the mRNA levels of EGFR ligands (EGF and amphir-
egulin), HER3 ligand (NRG1), and IGF-1R ligand (IGF) in cells using
qRT-PCR. Our data showed (Figure 4A) that expression levels of EGF
mRNA in both resistant cells were about two-fold higher than those in
the parental H3122 cells; CHR H3122 and LDKR H3122 cellsFigure 5. The NRG1-HER3-EGFR axis is responsible for activate
concentrations of NRG1 and alectinib/ceritinib were added to cell cult
were analyzed by Western blot with the indicated primary antibo
immunoprecipitation study; p-EGFR/p-HER3 was used as primary a
products. (D) Efficient knockdown of HER3 by three different siR
knockdown H3122 cells were incubated with stepwise increased con
for 4 days. WST was performed to evaluate cell viabilities.expressed two- and six-fold higher IGF mRNA, respectively, than the
parental cell line; and both resistant cell lines expressed more than
eight-fold higher NRG1 mRNA than the parental cell line.
To investigate if the increased ligands could induce drug resistance, we
exogenously added 100 ng/ml [24–27] of one of these ligands (EGF,
amphiregulin, NRG1, IGF) to the cell culture media of the parental
H3122 cells. As shown in Figure 4B, parental cells became resistant to
ALK inhibitors in the presence of NRG1 but not EGF, amphiregulin, or
IGF. In fact, NRG1 at concentrations as low as 200 pg/ml was sufficient
to induce theH3122 parental cell line to become resistant to alectinib and
ceritinib (Figure 4,C and D). Additionally, NRG1 also induces the
H3122 parental cells to become resistant to AP26113 and PF06463922,
two new-generation ALK inhibitors in clinical development.
Hence, our data showed that increased expression of NRG1, but not
EGF, amphiregulin, or IGF, is a major contributor to the adaptive
resistance of the H3122 cells to new-generation ALK inhibitors.
The NRG1-HER3-EGFR Axis Responsible for Resistance to
New Generation ALK Inhibitors
As an important ligand for HER3 receptor, NRG1 can activate the
HER3-AKT pathway [28,29]. Indeed, in the parental H3122 cells,
exogenous NRG1 induced an increase of p-HER3 and p-AKTd EGFR family–induced drug resistance. (A and B) Indicated
ure media. Cells were incubated for 1 hour and lysed, and proteins
dies. (C) One thousand micrograms of protein was isolated for
ntibody to detect its expression in the HER3/EGFR pulled-down
NA constructs in H3122 cells. (E and F) H3122 cells and HER3
centrations of ALK inhibitors in the presence of 100 ng/ml of NRG1
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inhibit p-HER3 and p-AKT and in fact increased p-HER3 in either
the presence or absence of NRG1 (Figure 5A and B).
It has been reported that the NRG1-EGFR-HER3 autocrine
signaling axis can mediate acquired lapatinib resistance in HER2-
positive breast cancer models [30]. We therefore investigated if there
is an interplay between activated EGFR and HER3 in the resistant
cells. In both resistant cell lines but not in the parental cell line, we
detected p-EGFR presence in the HER3 pulled-down complexes, and
conversely, p-HER3 was also detected in EGFR pulled-down
complexes. These data suggest the formation of HER3-EGFR
heterodimer in both resistant cell lines.
To investigate if NRG1-induced resistance is HER3 dependent,
we knocked down HER3 by siRNA in the parental cells and tested
the sensitivity of alectinib and ceritinib in both parental and HER3
knocked-down cells (Figure 5D). Our data (Figure 5E and F) showed
that effective knockdown of HER3 reverses the resistance of the
H3122 cells induced by NRG1 to both ALK inhibitors. In addition,
we employed Karpas 299 and SU-DHL-1 cell lines, two anaplastic
large cell lymphoma cell lines which harbor ALK fusion gene
(NPM-ALK) but express only a very low level of HER3, to test the
sensitivities of these ALK inhibitors in these two cell lines in the
presence of NRG1 (Supplementary Information 2) and found that
NRG1 did not affect the sensitivities to ALK inhibitors in these two
anaplastic large cell lymphoma cell lines. Taken together, our data
support a key role of HER3 in NRG1-mediated resistance to alectinib
and ceritinib, and the NRG1-HER3-EGFR axis is an important
mechanism mediating activation of bypass RTK pathways and
resistance to these ALK inhibitors.
Overcoming Resistance to ALK Inhibitors Using EGFR-Family
Tyrosine Kinase Inhibitors (TKIs)
Our results highlight that the NRG1-HER3-EGFR axis is an
important mechanism of resistance to these new-generation ALK
inhibitors and suggest that an inhibitor targeting this axis could be
effective in overcoming such resistance.
Because there is no specific NRG1 inhibitor available, we
investigated if EGFR-family TKIs can overcome the resistance to
ALK inhibitors. We evaluated several EGFR inhibitors, either already
FDA approved or currently in clinical trials (Table 1), including
erlotinib (a first-generation EGFR inhibitor), afatinib (a second-generation
irreversible EGFR inhibitor that targets wild-type EGFR, the T790M
EGFR mutant, and HER2), AZD9291 (a third-generation irreversible
EGFR inhibitor selectively targeting the T790M EGFR mutant), and
AZD8931 (a reversible, ATP competitive broad-spectrum inhibitor of
EGFR, HER2, and HER3).
Whereas each of these EGFR inhibitors as a single agent had only a
moderate effect at concentrations as high as 1 μM in the CHR
H3122 resistant cell line, combination of these EGFR inhibitors at
500 nM with alectinib can partially overcome the resistance toTable 1. EGFR Inhibitors Used in This Study.
E G F R
Inhibitors
IC50 on Different EGFR Family Members
EGFR (L858R) EGFR (wt) HER2
AZD9291 11.4 nM 493 nM NA
AZD8931 NA 4 nM 3 nM
Afatinib 0.4 nM 0.5 nM 14 nM
Erlotinib 2 nM 29 nM NAalectinib (Figure 6B). Interestingly, whereas these EGFR inhibitors as
a single agent had a greater effect at 1 μM in the LDKR H3122 cell
line than in the CHR H3122 cell line, their combination with
ceritinib only had an additive effect in overcoming resistance of the
LDKR 3122 cells to ceritinib (Figure 6C).
In both the CHR H3122 and LDKR H3122 cells, afatinib at 500
nM is effective in overcoming resistance, and we next determined the
minimal concentration needed for afatinib to overcome resistance of
ALK inhibitors in these two resistant cell lines. Our data showed that
afatinib at concentrations as low as 31.25 nM already achieved the
maximum effect in inhibition of cell growth in its combination with
alectinib or ceritinib in these two resistant cell lines (Figure 6, B and
C). Additionally, concurrent treatment of alectinib or ceritinib with
afatinib helped to eradicate the remaining cell population obtained
from treatment with an ALK inhibitor alone in the H3122 parental
cell line (Supplementary Information 3). Western blotting analysis
showed that although combination of alectinib with either afatinib or
afatinib can effectively block the EGFR Tyr 1068 phosphorylation,
the former combination is more effective than the latter in inhibition
of p-EGFR, providing a mechanistic explanation for the strong
synergistic effect between alectinib and afatinib in CHR H3122
resistant cells (Figure 6, D and E).
Discussion
Crizotinib, the first ALK inhibitor approved as a targeted therapy for
NSCLC [2], showed impressive clinical responses in patients harboring
ALK gene fusion. However, ALK fusion–positive patients developed
resistance to crizotinib fairly quickly, highlighting a clear need to develop
new treatment strategies to combat crizotinib-resistance. Investigations
into possible resistance mechanisms to crizotinib have identified
mutations of ALK in its kinase domain as a major mechanism.
Accordingly, second-generation ALK inhibitors alectinib and ceritinib
were developed and were shown to be effective in overcoming most of
the resistant ALK mutations developed during crizotinib treatment
[13,15]. Despite their impressive clinical data, recent studies have also
revealed that clinical resistance began to develop to these second-gen-
eration ALK inhibitors, and novel ALK mutations have been found in
patients who developed resistance to these second-generation ALK
inhibitors [18–21]. Interestingly, not all of the patients who developed
resistance to these second-generation ALK inhibitors have a novel ALK
mutation [13].
To investigate resistance mechanisms for these second-generation
ALK inhibitors, we obtained two resistant cell lines using the H3122
NSCLC cell line harboring the EML4-ALK variant 1 fusion gene and
alectinib and ceritinib. After a 5-month treatment of the H3122
NSCLC cells with a relatively high concentration (1 μM) of alectinib,
we obtained a resistant cell line (the CHR H3122 cell line), and after
a 7-month treatment of the H3122 NSCLC cells with 1 μM of
ceritinib, we obtained a second resistant cell line (the LDKR H3122
cell line). Both of these two resistant cell lines are approximately 10Reversibility Clinical Development Stage
HER3
NA No Phase III
4 nM Yes Phase I
NA No Approved for NSCLC
NA Yes Approved for EGFR mutated NSCLC
Figure 6. Combination treatment to overcome resistance. (A) Both resistant cell lines CHR H3122 and LDKR H3122 were seeded in
96-well plates and cultured with indicated single drugs or 500 nM combination drugs for 4 days; WST assay was then performed. (B and C)
Different concentrations of afatinib (from 31.25 nM to 500 nM)were combinedwith ALK inhibitors and added to cell culturemedia for 4 days.
Viability was assessed by WST assay. (D and E) Proteins were collected after treatment with the indicated drugs for 2 hours, and
immunoblotting was performed. Combination with afatinib induced downregulation of p-EGFR and its downstream signals.
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ceritinib. To examine if these resistant cell lines also become
insensitive to other new-generation ALK inhibitors in clinical
development, we tested AP26113 and PF06463922. AP26113 [22]
has been reported to be a dual inhibitor of ALK and EGFR mutants,
and PF06463922 [23] has been reported to be effective against all
known ALK-resistant mutations. Our data showed that both of these
resistant cell lines become much less sensitive to AP26113 and
PF06463922 than the parental H3122 cell line, suggesting that the
resistance developed with alectinib and ceritinib in the H3122 cell
line cannot be overcome by other ALK inhibitors. These data showed
that resistance to second-generation ALK inhibitors can indeed be
developed, although an extended treatment time may be necessary.
Investigations into the possible resistance mechanisms in these two
resistant cell lines failed to identify any ALK mutation in its kinase
domain. Instead, we found increased activation of p-ALK and some
other RTKs such as p-EGFR, p-HER3, and p-IGF-1R in both resistant
cell lines, and both alectinib and ceritinib became ineffective inhibitors
of p-AKT and p-ERK in both resistant cell lines (Figures 2 and 3).
Activation of alternative RTKs (EGFR, KIT, and IGF-1R) has been
reported to mediate crizotinib resistance in both clinical and preclinical
studies [9,11,24,25], but whether or not these RTKs can mediate
resistance to these second-generation ALK inhibitors was not known.
We next investigated how the bypass pathways were activated. The
EGFR ligands (EGF, amphiregulin), IGF-1R ligand (IGF), and
c-Met ligand (HGF) have been reported to be increased in cell culture
media and to contribute to bypass pathways of RTK activation
[9,25,27]. Higher concentrations of EGFR ligands were also reported
in the supernatant fluid from crizotinib-resistant patients with
malignant pleural effusion [10]. In the current study, we detectedincreased mRNA expression of NRG1, EGF, and IGF in both
resistant cell lines (Figure 3).
Among all the upregulated ligands, we found that NRG1 expression
was increased by more than eight-fold in both resistant cell lines.
Furthermore, our data showed that exogenous NRG1, but not EGF
and IGF, can cause the parental H3122 cells to become resistant to all
second-generation ALK inhibitors (Figure 4), highlighting NRG1
upregulation as an important contributor to the development of
resistance to these second-generation ALK inhibitors. Our finding is
consistent with recent studies which showed that NRG1 is a resistance
driver in ALK-dependent lung cancer cell systems [26,31].
NRG1 is a ligand for HER3, and the autocrine loop between
HER3 and NRG1 has been reported in ovarian, head and neck,
melanoma, and prostate cancers [28,29,32,33]. In this study, we
show that NRG1 indeed induces upregulation of p-HER3, which
abrogates the effective inhibition of downstream p-AKT achieved by
ALK inhibitors in the parental H3122 cells (Figure 5). Furthermore,
knockdown of HER3 in the parental H3122 cells blocked
NRG1-induced drug resistance, and in ALK-positive but HER3-
negative cell lines, and NRG1 failed to induce resistance. Collectively,
these results demonstrate that the resistance induced by NRG1 to
ALK inhibitors is HER3 dependent.
We investigated the interplay between HER3 and other EGFR
family members. As a pseudokinase, HER3 can form heterodimers
with other EGFR family members and lead to activation of other
EGFR members [30,34–36]. Our RTK assay did not detect
phosphorylated HER2 expression in the resistant cells (Figure 3A).
We also investigated the p-HER2 expression using Western blot but
failed to detect p-HER2 expression, strongly suggesting that HER2 is
not a contributor to ALK resistance. Since both EGFR and HER3
170 Resistance Mechanisms to ALK Inhibitors in NSCLC Dong et al. Neoplasia Vol. 18, No. 3, 2016were activated in the resistant cells (Figure 3), and the EGFR-HER3
heterodimer was previously shown to be involved in acquired
lapatinib resistance in HER2-positive breast cancer models [30], we
then asked if the EGFR-HER3 heterodimer contributes to the
activation in the resistant cells. We detected p-EGFR in the HER3
protein complexes in both ALK-resistant cells but not in the parental
H3122 cells (Figure 5), and found that treatment of the resistant cells
with an EGFR inhibitor (afatinib) decreased p-EGFR, as well as
p-HER3 (Figure 6, D and E). These data suggest that EGFR is
important in maintaining HER3 activation in the resistant cells.
Based upon our data, we propose that the NRG1-HER3-EGFR
axis plays a key role in mediating the resistance to second-generation
ALK inhibitors. Interestingly, although AP26113 is a ALK/EGFR
dual inhibitor, it showed limited activity in overcoming alectinib and
ceritinib resistance (Figure 1D).
We next tested strategies to combat the resistance by targeting the
NRG1-HER3-EGFR axis. To date, no specific NRG1 inhibitor has been
reported. Mohamad Younes et al. recently reported that tumor cells
expressing NTS (NRG1) were responsive to EGFR inhibitors and that
EGFR TKIs could reduce EGFR family expression and their downstream
molecules [37]. We therefore evaluated a number of FDA-approved or
clinically developed small-molecule inhibitors of the EGFR family
proteins in combination with ALK inhibitors. Our data showed that
several EGFR inhibitors are very effective in overcoming alectini-
b-induced drug resistance and afatinib is the most effective in
overcoming ceritinib-induced drug resistance (Figure 6). Combina-
tion of afatinib with either alectinib or ceritinib effectively eliminates the
remaining small population of tumor cells when treated with an ALK
inhibitor alone in the H3122 parental cell line. Since afatinib has been
approved for clinical use in late-stageNSCLC patients a combination of
afatinib and ALK inhibitors can be tested in the clinic in patients who
develop resistance to ALK inhibitors but lack detectable ALK-resistant
mutations.
Conclusion
In the present study, we investigated the mechanisms of acquired
resistance of alectinib and ceritinib, two second-generation ALK
inhibitors, in the H3122 NSCLC cell line harboring the EML4-ALK
variant 1 fusion in vitro. Our data showed that alectinib and ceritinib
can develop resistance in the H3122 cells, although prolonged drug
treatment was needed. While mutations of ALK in its kinase domain are
a common resistance mechanism for crizotinib, the first-generation
ALK inhibitor, we did not detect any ALK mutation in these resistant
cell lines. Instead, overexpression of phospho-ALK and alternative
RTKs such as phospho-EGFR, phospho-HER3, and phos-
pho-IGFR-1R was observed in resistant cell lines. Furthermore, we
found that NRG1, a ligand for HER3, is upregulated and responsible
for resistance by activating the EGFR family pathways through the
NRG1-HER3-EGFR axis. Combination treatment of an ALK
inhibitor with an EGFR inhibitor, in particular afatinib, a potent
inhibitor of both wild-type and mutated EGFR, can effectively
overcome resistance. Our study provides new mechanistic insights
into adaptive resistance to these second-generation ALK inhibitors and
suggests a potential clinical strategy to combat resistance ALK-positive
lung cancer cells to these second-generation ALK inhibitors in NSCLC.
Appendix A. Supplementary data
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